NYSE - Delayed Quote USD

Emergent BioSolutions Inc. (EBS)

2.1800 -0.1100 (-4.80%)
At close: April 24 at 4:00 PM EDT
2.2500 +0.07 (+3.21%)
Pre-Market: 4:45 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,023,000.0000
1,023,000.0000
1,076,100.0000
1,639,400.0000
1,462,200.0000
Cost of Revenue
705,400.0000
705,400.0000
693,100.0000
748,100.0000
537,000.0000
Gross Profit
317,600.0000
317,600.0000
383,000.0000
891,300.0000
925,200.0000
Operating Expense
519,100.0000
519,100.0000
546,300.0000
508,200.0000
486,700.0000
Operating Income
-201,500.0000
-201,500.0000
-163,300.0000
383,100.0000
438,500.0000
Net Non Operating Interest Income Expense
-87,900.0000
-87,900.0000
-37,300.0000
-34,500.0000
-31,300.0000
Other Income Expense
-441,800.0000
-441,800.0000
-18,400.0000
-45,400.0000
4,700.0000
Pretax Income
-731,200.0000
-731,200.0000
-219,000.0000
303,200.0000
411,900.0000
Tax Provision
29,300.0000
29,300.0000
-7,400.0000
83,700.0000
106,100.0000
Net Income Common Stockholders
-760,500.0000
-760,500.0000
-211,600.0000
219,500.0000
305,800.0000
Diluted NI Available to Com Stockholders
-760,500.0000
-760,500.0000
-211,600.0000
219,500.0000
305,800.0000
Basic EPS
-14.85
-14.85
-4.22
4.10
5.80
Diluted EPS
-14.85
-14.85
-4.22
4.06
5.68
Basic Average Shares
51,200.0000
51,200.0000
50,100.0000
53,500.0000
52,700.0000
Diluted Average Shares
51,200.0000
51,200.0000
50,100.0000
54,100.0000
53,800.0000
Total Operating Income as Reported
-726,400.0000
-726,400.0000
-170,000.0000
341,400.0000
438,500.0000
Total Expenses
1,224,500.0000
1,224,500.0000
1,239,400.0000
1,256,300.0000
1,023,700.0000
Net Income from Continuing & Discontinued Operation
-760,500.0000
-760,500.0000
-211,600.0000
219,500.0000
305,800.0000
Normalized Income
-404,447.0000
-404,447.0000
-205,101.0000
249,524.0000
305,800.0000
Interest Expense
87,900.0000
87,900.0000
37,300.0000
34,500.0000
31,300.0000
Net Interest Income
-87,900.0000
-87,900.0000
-37,300.0000
-34,500.0000
-31,300.0000
EBIT
-643,300.0000
-643,300.0000
-181,700.0000
337,700.0000
443,200.0000
EBITDA
-518,200.0000
-518,200.0000
-38,400.0000
461,500.0000
557,700.0000
Reconciled Cost of Revenue
645,900.0000
645,900.0000
609,700.0000
682,800.0000
482,300.0000
Reconciled Depreciation
125,100.0000
125,100.0000
143,300.0000
123,800.0000
114,500.0000
Net Income from Continuing Operation Net Minority Interest
-760,500.0000
-760,500.0000
-211,600.0000
219,500.0000
305,800.0000
Total Unusual Items Excluding Goodwill
-450,700.0000
-450,700.0000
-6,700.0000
-41,700.0000
--
Total Unusual Items
-450,700.0000
-450,700.0000
-6,700.0000
-41,700.0000
--
Normalized EBITDA
-67,500.0000
-67,500.0000
-31,700.0000
503,200.0000
557,700.0000
Tax Rate for Calcs
0.0002
0.0002
0.0000
0.0003
0.0003
Tax Effect of Unusual Items
-94,647.0000
-94,647.0000
-201.0000
-11,676.0000
--
12/31/2020 - 11/15/2006

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AMRX Amneal Pharmaceuticals, Inc.
6.05
+12.04%
 
SIGA SIGA Technologies, Inc.
8.66
-1.14%
 
EGRX Eagle Pharmaceuticals, Inc.
4.5500
-4.61%
 
ESPR Esperion Therapeutics, Inc.
2.1300
+1.91%
 
SBFM Sunshine Biopharma, Inc.
0.9300
-23.14%
 
DVAX Dynavax Technologies Corporation
11.42
-2.89%
 
PRGO Perrigo Company plc
31.23
+2.43%
 
NBIX Neurocrine Biosciences, Inc.
138.97
-0.80%
 
ELTP Elite Pharmaceuticals, Inc.
0.1263
+2.52%
 
AQST Aquestive Therapeutics, Inc.
3.9000
-8.88%